Silvia
Jiménez Cabrera
Profesora Asociada CC. Salud
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaHospital Universitari Germans Trias i Pujol -ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2019
-
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620